Chinese CDMO GenScript Biotech opened a new biologics clinical supply manufacturing facility even as it is working on a commercial supply facility.
Bayer's revamp just took another big step forward. After selling off Coppertone, the company agreed to hive off Dr. Scholl’s for $585 million.
Bayer is recalling two lots of its top-selling drugs after a labeling mishap led to them being filled with the wrong hemophilia medicines.
Roche has licensed Tamiflu to Sanofi, not in its current prescription status, but potential over-the-counter rights in the U.S.
Amarin is doubling down on its heart drug Vascepa, aiming to raise $400 million-plus in a stock offering. But investors aren't thrilled with the idea.
Biohaven Pharmaceuticals has been unexpectedly hit by a complete response letter for using an Apotex API.
Otezla won the first FDA approval for oral ulcers associated with Behçet’s Disease. It's the third indication for Celgene's up-for-sale med.
Pfizer's Lyrica has had a long, multibillion-dollar run. But now, with generics hitting the U.S., that megablockbuster history is nearing its end.
Johnson & Johnson is defending against around 14,200 lawsuits alleging harm from talc, and the company plans to challenge expert evidence Monday.
Be sure to submit your nominations by 11:59 p.m. EDT Monday, Aug. 19, for consideration in this year’s list.
